Mithra Pharmaceuticals SA
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mithra Pharmaceuticals SA
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
Mithra’s new CEO has immediately signaled a potential sale for the firm’s generics business as it looks to focus on branded assets in women’s health. Meanwhile, Sawai has reorganized its management team, the longtime chair of Viatris is moving on to another role, and a former AAM vice-president has joined Sandoz.
Mayne Pharma and partner Mithra have announced the launch of their Haloette generic version of NuvaRing in the US, adding further competition to a field that already includes Amneal and Teva as well as Prasco’s authorized generic.
Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.
- Other Names / Subsidiaries
- Estetra SA
- Estetra SPRL
- Mithra IBD SA
- Mithra RDP SA
- Mithra Pharmaceuticals CDMO
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.